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ORIGINAL ARTICLE
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Abstract
Benzenesulfonamides incorporating cyanoacrylamide moieties with activity against
tumour-associated human (h) isoforms hCA IX and XII (which are validated antitumor targets)
were investigated for their quantitative structural activity relationships (QSAR). Multiple linear
regression analysis was used to develop model relationships between molecular descriptors
and inhibition constants (Ki). The molecular geometry optimization were performed on all
molecules at DFT-B3LYP/6-311++G(d,p) level. Over 1250 molecular descriptors were calculated
using Gaussian 09, Hyperchem and EDRAGON programs. Multiple linear regression equations
have been developed and validated using leave-one-out cross-validated technique. The derived
QSAR models are found to be statistically significant and show good predictive ability.
Keywords
Benzenesulfonamides derivatives, carbonic
anhydrase isoforms hCA IX and XII, DFT,
MLR, QSAR descriptors
History
Received 8 June 2014
Revised 14 July 2014
Accepted 22 July 2014
Published online 3 September 2014
Introduction
Cancer is a major health problem which alarms the medical
community all over the globe, and is projected to become the
principal cause of death in the coming next few years1–4. In spite
of the extensive progress in many aspects of cancer research,
conventional chemotherapy is highly inadequate5–7. Newer drug
entities with novel targets and mechanism of action are urgently
needed8–12. The tumor associated carbonic anhydrase (CA),
especially CA IX and CA XII isoforms are known to be
interesting tumor markers and their inhibitory action leads
them to be promising antineoplastic agents, diagnostic tools for
non-invasive in vivo tumor imaging and marking hypoxic
tissues13–17.
Recently, we have developed a new series of Tyrphostine- Type
small molecules aiming to locate multiple tumor pathways
inhibition to combat the multiple misregulated tumor growth
and survival pathways18. In this respect, interesting derivatives
with variable degrees of activity and affinity towards four CA
isoforms were identified19 and work is in progress to look for their
potential technological applications.
Computer aided drug design methodologies (CADD), such as
quantitative structure-activity relationship (QSAR) and/ quantita-
tive structure-property (QSPR) relationship, are undeniably
prodigious quantum chemical studies of the modern day chem-
istry and biochemistry. QSAR/QSPR may help estimate biological
activity data, cutting down cost and time consuming synthetic
procedures, and predicting pharmacokinetic as well as pharma-
codynamics profiles and ultimately constituting an important tool
in design and development of new drug and novel leads. To
achieve a convincing correlation, it is vital that only the relevant
descriptors be used. Descriptors reflect simple molecular proper-
ties and in general can cater an insight into physicochemical
attributes of activity20.
In our previous study, we had synthesized several
benzenesulfonamides incorporating cyanoacrylamide moieties
(tyrphostine analogues), and reported the new benzenesulfona-
mides obtained which were evaluated as the low nano-molar or
sub-nanomolar CA IX/XII inhibitors19. The aim of present study
is to find the main structural parameters of twenty-two
benzenesulfonamides incorporating cyanoacrylamide moieties
(Table 1) which are responsible for the inhibitory action against
tumor associated carbonic anhydrase hCA IX/XII and to establish
statistically significant mathematical models for their biological
activities in terms the molecular descriptors. The results of this
study may lead to synthesis of novel tumor associated isoforms
hCA IX/XII inhibitor benzenesulfonamides.
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Materials and methods
Experimental data set
The present QSAR study is in continuation to our earlier work on
benzenesulfonamide derivatives incorporating cyanoacrylamide
moieties19. Which were synthesized for an action against tumor
associated isoforms human carbonic anhydrase hCA IX and hCA
XII. A dataset of 22 benzenesulfonamide derivatives presented
in Table 2 was prepared and evaluated in terms of ability as a
potent drug against tumor associated isoforms human carbonic
anhydrase hCA IX and hCA XII.
Geometry optimization and molecular descriptors
calculation
The initial conformations of the compounds have been drawn by
means of the Gauss view 5.0.8 program21 software and then 3D
structures were optimized by employing Becke’s three parameter
hybrid exchange functional22 with Lee–Yang–Parr correlation
functional (B3LYP)23,24 of DFT25 and using 6–311++G(d,p)
basis set with the help of Gaussian 09 software26 available
at Central Facility for Computational Research (Cluster),
University of Lucknow. After geometry optimization, several
physiochemical parameters were calculated with Hyperchem
software27.
A pool of molecular parameters (over 1250) including
different group and class of 3D descriptors such as constitutional,
walk and path counts, information indices, connectivity indices,
topological, radial distribution function (RDF), 2D autocorrel-
ation edge adjacency indices, Eigen value-based indices,
topological charge indices, 3D-MoRSE, WHIM, GATAWAY,
functional group counts, charge molecular properties, atom
centered fragment and other group of descriptors have been
calculated using, HYPERCHEM27 and EDRAGON28 software.
We have also included five descriptors obtained from DFT
calculation (total energy, energy of HOMO and LUMO,
HOMO-LUMO gap, and molecular dipole moment) in the
analysis.
Statistical analysis
In the present study, the statistical software package SPSS 2129
has been used for conducting Multiple linear regression (MLR)
analysis. MLR analysis with stepwise selection and elimination of
variables was employed to develop the best QSAR model. The
MLR technique was performed on the set of molecules shown in
Table 1. MLR analysis provides a useful equation based upon
different quantum chemical descriptors that can be used to predict
the Ki of Benzenesulfonamide derivatives. Cross-validation
technique with leave-one-out (loo) method30 was used to verify
the statistical significance and predictive ability of the developed
model.
Table 1. Benzenesulfonamides incorporating cyanoacrylamide moieties
used for QSAR analysis against hCA IX and XII.
Table 2. Experimental and predicted inhibition constants of
benzenesulfonamides against human carbonic anhydrase (hCA)
isoforms IX and XII along with residuals.
Ki(nM)
hCA IX hCA XII
Mol.
S. No. Exp.
Pred.
(Equation 1) Res. Exp.
Pred.
(Equation 2) Res.
1 05.20 04.40 00.80 00.67 01.35 00.68
2 08.90 09.70 00.80 00.86 00.11 00.75
3 35.60 34.40 01.20 00.72 00.55 00.17
4 00.93 01.60 02.53 00.66 00.41 01.07
5 32.60 29.30 03.30 00.60 00.67 00.07
6 00.86 00.90 01.76 00.57 00.50 00.07
7 20.50 18.90 01.60 00.59 00.98 00.39
8 00.96 01.30 00.34 00.67 00.23 00.90
9 07.80 08.20 00.40 00.53 00.84 00.31
10 21.20 25.10 03.90 02.30 01.29 01.01
11 05.40 05.80 00.40 05.20 04.20 01.00
12 00.65 00.40 01.05 02.30 02.09 00.21
13 00.67 02.30 01.63 00.65 02.06 01.41
14 03.40 06.20 02.80 00.93 01.86 00.93
15 04.90 06.80 01.90 02.40 02.53 00.13
16 04.30 05.80 01.50 06.30 06.00 00.30
17 03.70 02.10 01.60 06.40 07.16 00.76
18 09.50 05.90 03.60 08.90 09.23 00.33
19 12.80 12.80 00.00 24.30 23.98 00.32
20 09.50 10.70 01.20 03.50 03.71 00.21
21 05.80 08.40 02.60 11.70 11.54 00.16
22 00.33 00.30 00.03 00.64 01.38 00.74
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Results and discussion
The chemical structure of the 22 compounds considered for the
current study is given in Table 1. The structural descriptors for the
22 benzenesulfonamides were computed by the procedure as
explained in material and method section and the Pearson’s
correlation matrix was performed on all descriptors for selection
of a set of appropriate descriptors. The analysis of the matrix
revealed 12 descriptors for the development of MLR models.
Step-wise multilinear regression analysis on these 12 molecular
descriptors revealed the following two statistically significant
independent parametric QSAR equations for biological activity
(inhibition constant of title compounds against tumor associated
human carbonic anhydrase isoform hCA IX and hCA XII) in
terms of structural descriptors. Model 1 (for hCA IX)
Ki ¼ 180:578 þ 448:427  E1p þ 143:313  HATS7u
 171:384  HATS7m þ 2:977  RDF125m
 149:258  R8p  34:310  GATS4e
ð1Þ
(N¼ 22, r¼ 0.980, r2¼ 0.961, s¼ 2.336, F¼ 61.871, p5107)
where E1p is 1st component accessibility directional WHIM
index, weighted by polarizability (WHIM descriptor), HATS7u –
leverage-weighted autocorrelation of lag 7/ un-weighted
(GETAWAY descriptors), HATS7m – leverage-weighted auto-
correlation of lag 7/weighted by mass (GETAWAY descriptors),
RDF125m –Radial Distribution Function – 125/weighted by mass
(RDF descriptors), R8p – R autocorrelation of lag 8/weighted by
polarizability (GETAWAY descriptors), GATS4e – Geary auto-
correlation of lag 4 weighted by Sanderson electronegativity (2D
autocorrelations). The QSAR Model1 (Equation 1) suggests that
the positive correlation coefficient of structural parameters E1p,
HATS7u, RDF125m show a direct relationship with biological
activity i.e. inhibition constant Ki. Parameters like HATS7m, R8p
have negative correlation coefficient with inverse relationship for
Ki. Model 2 (for hCA XII)
Ki ¼ 288:639  731:700  X1A þ 259:252  Gu
 4:391  RDF030v  14:385  Mor08v
þ 37:907  HATS6p  41:660  G3m
ð2Þ
(N¼ 22, r¼ 0.992, r2¼ 0.985, s¼ 0.804, F¼ 106.28, p5107)
where X1A is average connectivity index of order 1(Connectivity
indices), Gu – total symmetry index/un–weighted (WHIM
descriptors), RDF030v – Radial Distribution Function – 030/
weighted by van der Waals volume (RDF descriptors), Mor08v–
signal 08/weighted by van der Waals volume (3D–MoRSE
descriptors), HATS6p – leverage-weighted autocorrelation of
lag 6/weighted by polarizability (GETAWAY descriptor) and
G3m – 3rd component symmetry directional WHIM index/
weighted by mass (WHIM descriptors). The QSAR Model 2 for
hCAXII indicates that the descriptors Gu and HATS6p have
positive correlation coefficients whereas the remaining descrip-
tors have negative correlation coefficients, implying the direct and
inverse effect on the inhibition constant Ki values respectively.
To check the credibility of the models, several parameters are
used, such as regression coefficient (r), adjusted square correl-
ation coefficient (r2adj), standard error of estimate (S), value of
Fischer’s value (F), significance level (p)50.005. The large value
of F, small value of S, even very small p value, and r2 close to 1,
all indicate the good predictability of the QSAR model. Both the
developed QSAR models are statistically significant, the signifi-
cance level being (p)5107. The value of multiple correlation
coefficient (r) is found to be 0.980 and 0.992 for QSAR model 1
and 2 respectively and it supports the predictive/estimation ability
of the both QSAR model (Equations 1 and 2).
The structural parameters used in Equations 1 and 2 are
provided in Table S1 (supplementary material). Experimental and
predicted values of the inhibition constant (Ki) for both carbonic
anhydrase inhibition are given here in Table 2 along with
residuals.
Determination of predictive ability of the developed model
needs its validation. To estimate the prediction ability of model by
means of an internal validation procedure cross validation is
conducted. In order to test the validity of the predictive power of
selected MLR models (Equations 1 and 2), the leave-one-out
technique (LOO technique) was used. The developed models
were validated by calculation of the following statistical
parameters: predicted residual sum of squares (PRESS), total
sum of squares deviation (SSY), standard deviation of predicted
error and cross-validated correlation coefficients (r2cv and r
2
adj;
Table 3).
PRESS also termed as q2 is an important cross-validation
parameter as it is a good approximation of the real predictive error
of the models. Its value being less than total sum of square (SSY)
points out that model predicts better than chance and can be
considered statistically significant. Smaller the PRESS value
means the better of the model predictability. The results depicted
in Table 3, confirm that the model 1 and 2 are statistically
significant.
Further, for reasonable QSAR model, the PRESS/SSY ratio
should be lower than 0.4. The ratio of PRESS/SSY in the present
QSAR study are 0.083 and 0.033 for the first and second model,
respectively. The predictive ability of both model is also
corroborated by the leave-one-out cross validation, square
correlation coefficient (r2loocv ¼ 0.917 and 0.967 for model 1
and model 2 respectively) being very close to adjusted square
correlation coefficient (r2adj) for both the models. The agreement
between the values of r2loocv and r
2
adj is an essential criterion for
the best qualification of the QSAR models 1 and 2.
Figures 1 and 2 show the plots of linear regression predicted
values of inhibition constant (Ki) versus the experimental Ki
values of the benzenesulfonamides incorporating cyanoacryla-
mide moieties with biological activity. The correlation plots
between experimental and the predicted data from the derived
multiple regression QSAR Equation 1 and 2 given in Figures 1
and 2 respectively, indicate that the predicted values are much
closer to experimental one. This confirms that the models 1 and 2
can be successfully applied to predict inhibition constant of other
benzenesulfonamides incorporating cyanoacrylamide moieties
against tumour-associated human (h) isoforms hCA IX and XII.
Conclusion
Statistically significant QSAR models describing the structure –
carbonic anhydrase inhibition activity relationship in benzene-
sulfonamide derivatives incorporating cyanoacrylamide groups
have been derived. The validity of the models has been
Table 3. Cross-validation parameters.
Model for PRESS SSY PRESS/SSY Sloo-cv r
2
loocv r
2
adj r
2
adj–r
2
loocv
hCA IX 175.0 2108.0 0.083 2.886 0.917 0.961 0.044
hCA XII 021.4 0647.3 0.033 1.011 0.967 0.985 0.018
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established by the determination of suitable leave-one-out-cross
validation (loo-cv) statistical parameters. The established models
were used to predict the inhibition constant of the compounds
under consideration and close agreement between experimental
and predicted values was accomplished. The low-residual activity
and large cross-validated values achieved suggests a decent
predictive ability of the developed QSAR models. It indicates that
the activity studied on benzenesulfonamide derivative series can
be successfully modelled using various WHIM, GETAWAY,
3D-MoRSE, RDF and 2D autocorrelations molecular descriptors.
The present study may lead to the synthesis of other potential
tumour associated isoforms hCA IX/XII inhibitor benzenesulfo-
namide derivatives.
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